Cronos Group Inc
Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.
Cronos Group Inc (CRON) - Net Assets
Latest net assets as of December 2025: $1.14 Billion USD
Based on the latest financial reports, Cronos Group Inc (CRON) has net assets worth $1.14 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.20 Billion) and total liabilities ($54.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.14 Billion |
| % of Total Assets | 95.47% |
| Annual Growth Rate | 81.31% |
| 5-Year Change | -14.34% |
| 10-Year Change | 4461.64% |
| Growth Volatility | 331.17 |
Cronos Group Inc - Net Assets Trend (2013–2025)
This chart illustrates how Cronos Group Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cronos Group Inc (2013–2025)
The table below shows the annual net assets of Cronos Group Inc from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.14 Billion | +2.88% |
| 2024-12-31 | $1.11 Billion | +1.36% |
| 2023-12-31 | $1.10 Billion | -3.93% |
| 2022-12-31 | $1.14 Billion | -14.49% |
| 2021-12-31 | $1.33 Billion | -21.89% |
| 2020-12-31 | $1.71 Billion | -2.34% |
| 2019-12-31 | $1.75 Billion | +1025.61% |
| 2018-12-31 | $155.39 Million | +126.24% |
| 2017-12-31 | $68.68 Million | +174.12% |
| 2016-12-31 | $25.06 Million | +197.13% |
| 2015-12-31 | $8.43 Million | +5.88% |
| 2014-12-31 | $7.96 Million | +779.66% |
| 2013-12-31 | $905.41K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cronos Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 44837547500.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $447.76 Million | 40.93% |
| Common Stock | $661.78 Million | 60.50% |
| Other Comprehensive Income | $-16.84 Million | -1.54% |
| Other Components | $1.21 Million | 0.11% |
| Total Equity | $1.09 Billion | 100.00% |
Cronos Group Inc Competitors by Market Cap
The table below lists competitors of Cronos Group Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TechMatrix Corporation
PINK:TMTMF
|
$513.62 Million |
|
Renew Holdings plc
PINK:RNWHF
|
$513.80 Million |
|
BRELY
OTCQX:BRELY
|
$513.83 Million |
|
CEWE Stiftung & Co. KGaA
XETRA:CWC
|
$513.84 Million |
|
Starhill Global Real Estate Investment Trust
PINK:SGLMF
|
$513.53 Million |
|
Zhejiang Provincial New Energy Investment Group Co Ltd
SHG:600032
|
$513.43 Million |
|
GuangDong Topstrong Living Innovation & Integration Co Ltd Class A
SHE:300749
|
$513.14 Million |
|
Jinlong Machinery Electronic
SHE:300032
|
$513.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cronos Group Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,064,063,000 to 1,093,897,000, a change of 29,834,000 (2.8%).
- Net loss of 9,447,000 reduced equity.
- Share repurchases of 9,911,521 reduced equity.
- Other comprehensive income increased equity by 46,683,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.45 Million | -0.86% |
| Share Repurchases | $9.91 Million | -0.91% |
| Other Comprehensive Income | $46.68 Million | +4.27% |
| Other Changes | $2.51 Million | +0.23% |
| Total Change | $- | 2.80% |
Book Value vs Market Value Analysis
This analysis compares Cronos Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.91x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 36.47x to 0.91x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.07 | $2.59 | x |
| 2014-12-31 | $0.25 | $2.59 | x |
| 2015-12-31 | $0.19 | $2.59 | x |
| 2016-12-31 | $0.32 | $2.59 | x |
| 2017-12-31 | $0.39 | $2.59 | x |
| 2018-12-31 | $0.90 | $2.59 | x |
| 2019-12-31 | $5.10 | $2.59 | x |
| 2020-12-31 | $4.87 | $2.59 | x |
| 2021-12-31 | $3.61 | $2.59 | x |
| 2022-12-31 | $3.03 | $2.59 | x |
| 2023-12-31 | $2.89 | $2.59 | x |
| 2024-12-31 | $2.76 | $2.59 | x |
| 2025-12-31 | $2.84 | $2.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cronos Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.89%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.09x
- Recent ROE (-0.86%) is above the historical average (-9.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -68.42% | 0.00% | -0.15x | 1.42x | $-710.02K |
| 2014 | -52.12% | 0.00% | -0.08x | 1.08x | $-4.95 Million |
| 2015 | 3.30% | 8.17% | 0.32x | 1.26x | $-564.98K |
| 2016 | -3.53% | -214.64% | 0.01x | 1.27x | $-3.39 Million |
| 2017 | -2.16% | -45.69% | 0.04x | 1.17x | $-8.35 Million |
| 2018 | -13.93% | -178.50% | 0.06x | 1.23x | $-37.16 Million |
| 2019 | 66.66% | 4911.60% | 0.01x | 1.19x | $991.52 Million |
| 2020 | -4.27% | -156.55% | 0.02x | 1.13x | $-244.27 Million |
| 2021 | -29.62% | -613.54% | 0.05x | 1.05x | $-529.83 Million |
| 2022 | -14.75% | -194.51% | 0.07x | 1.06x | $-283.12 Million |
| 2023 | -6.73% | -84.78% | 0.08x | 1.04x | $-183.92 Million |
| 2024 | 3.86% | 34.93% | 0.10x | 1.10x | $-65.33 Million |
| 2025 | -0.86% | -4.89% | 0.16x | 1.09x | $-118.84 Million |
Industry Comparison
This section compares Cronos Group Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cronos Group Inc (CRON) | $1.14 Billion | -68.42% | 0.05x | $513.53 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |